Medgenics (MDGN) says a poster presentation at the European Society of Gene and Cell Therapy Congress outlines new data that is "evidence of [the company's] success in advancing Biopump technology while improving performance and handling."
Essentially, MDGN says its second-generation gene therapy vectors enhance the "levels and durability" of protein secretion.
The company expects to "initiate human trials with a Biopump containing the second generation viral vector and new implantation protocol in H1 2014." (PR)
More on the Biopump here.
Poster presentation is here.